MSD partners with Seattle Genetics on two new oncology projects
Agreement grants MSD access to investigational ADC and a small molecule tyrosine kinase inhibitor
Read More
Tag: Seattle Genetics
NICE OKs three new therapies for blood cancer
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read More
US expands scope of Seattle Genetics’ Adcetris
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
